Neural cell adhesion molecule 1 is a cellular target engaged plasma biomarker in demyelinating Charcot-Marie-Tooth disease.
Charcot-Marie-Tooth disease
demyelinating neuropathy
neural cell adhesion molecule 1
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
03
02
2023
received:
08
09
2022
accepted:
22
02
2023
medline:
8
5
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
Elevated plasma concentrations of neural cell adhesion molecule 1 (NCAM1) and p75 neurotrophin receptor (p75) in patients with peripheral neuropathy have been reported. This study aimed to determine the specificity of plasma concentration elevation of either NCAM1 or p75 in a subtype of Charcot-Marie-Tooth disease (CMT) and its correlation with pathologic nerve status and disease severity. Blood samples were collected from 138 patients with inherited peripheral neuropathy and 51 healthy controls. Disease severity was measured using Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNSv2), and plasma concentrations of NCAM1 and p75 were analyzed by enzyme-linked immunosorbent assay. Eight sural nerves from CMT patients were examined to determine the relation of histopathology and plasma NCAM1 levels. Plasma concentration of NCAM1, but not p75, was specifically increased in demyelinating subtypes of CMT (median = 7100 pg/mL, p < 0.001), including CMT1A, but not in axonal subtype (5964 pg/mL, p > 0.05), compared to the control (3859 pg/mL). CMT1A patients with mild or moderate severity (CMTNSv2 < 20) showed higher levels of plasma NCAM1 than healthy controls. Immunofluorescent NCAM1 staining for the sural nerves of CMT patients showed that NCAM1-positive onion bulb cells and possible demyelinating Schwann cells might be associated with the specific increase of plasma NCAM1 in demyelinating CMT. The plasma NCAM1 levels in demyelinating CMT might be a surrogate biomarker reflecting pathological Schwann cell status and disease progression.
Sections du résumé
BACKGROUND AND PURPOSE
Elevated plasma concentrations of neural cell adhesion molecule 1 (NCAM1) and p75 neurotrophin receptor (p75) in patients with peripheral neuropathy have been reported. This study aimed to determine the specificity of plasma concentration elevation of either NCAM1 or p75 in a subtype of Charcot-Marie-Tooth disease (CMT) and its correlation with pathologic nerve status and disease severity.
METHODS
Blood samples were collected from 138 patients with inherited peripheral neuropathy and 51 healthy controls. Disease severity was measured using Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNSv2), and plasma concentrations of NCAM1 and p75 were analyzed by enzyme-linked immunosorbent assay. Eight sural nerves from CMT patients were examined to determine the relation of histopathology and plasma NCAM1 levels.
RESULTS
Plasma concentration of NCAM1, but not p75, was specifically increased in demyelinating subtypes of CMT (median = 7100 pg/mL, p < 0.001), including CMT1A, but not in axonal subtype (5964 pg/mL, p > 0.05), compared to the control (3859 pg/mL). CMT1A patients with mild or moderate severity (CMTNSv2 < 20) showed higher levels of plasma NCAM1 than healthy controls. Immunofluorescent NCAM1 staining for the sural nerves of CMT patients showed that NCAM1-positive onion bulb cells and possible demyelinating Schwann cells might be associated with the specific increase of plasma NCAM1 in demyelinating CMT.
CONCLUSIONS
The plasma NCAM1 levels in demyelinating CMT might be a surrogate biomarker reflecting pathological Schwann cell status and disease progression.
Substances chimiques
Biomarkers
0
Neural Cell Adhesion Molecules
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1745-1754Informations de copyright
© 2023 European Academy of Neurology.
Références
Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the inherited neuropathies consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2015;86(8):873-878.
Rossor AM, Shy ME, Reilly MM. Are we prepared for clinical trials in Charcot-Marie-tooth disease? Brain Res. 2020;1729:146625.
Morrow JM, Evans MRB, Grider T, et al. Validation of MRC Centre MRI calf muscle fat fraction protocol as an outcome measure in CMT1A. Neurology. 2018;91(12):E1125-E1129.
Millere E, Rots D, Simrén J, et al. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-tooth disease. Eur J Neurol. 2021;28:10-981.
Sandelius Å, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90(6):e518-e524.
Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the inherited neuropathies consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2015;5(8):873-878.
Huxley C, Passage E, Robertson AM, et al. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet. 1998;7(3):449-458.
Fledrich R, Schlotter-Weigel B, Schnizer TJ, et al. A rat model of Charcot-Marie-tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. Brain. 2012;135(1):72-87.
Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-tooth disease type 1A. Brain Res. 2000;123(7):1516-1527.
Kim YH, Kim YH, Shin YK, et al. p75 and neural cell adhesion molecule 1 can identify pathologic Schwann cells in peripheral neuropathies. Ann Clin Transl Neurol. 2019;6(7):1292-1301.
Svaren J, Moran JJ, Wu X, et al. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies. Ann Neurol. 2019;85(6):887-898.
Park HT, Kim JK, Tricaud N. The conceptual introduction of the “demyelinating Schwann cell” in peripheral demyelinating neuropathies. Glia. 2019;67(4):571-581.
Hanemann CO, Gabreëls-Festen AAWM, Stoll G, Müller HW. Schwann cell differentiation in Charcot-Marie-tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs. Acta Neuropathol. 1997;94(4):310-315.
Jennings MJ, Kagiava A, Vendredy L, et al. NCAM1 and GDF15 are biomarkers of Charcot-Marie-tooth disease in patients and mice. Brain. 2022;145:3999-4015.
Jessen KR, Mirsky R. Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia. 2008;56(14):1552-1565.
Hanemann CO, Gabreels-Festen AAWM, Miiller HW, Stoll G. Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages. Brain. 1996;119:1461-1469.
Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-tooth disease. J Peripher Nerv Syst. 2011;16(3):191-198.
Le FN, Lescs M-C, Gherardi RK. Anti-NKH-1 antibody specifically stains unmyelinated fibres and non-myelinating Schwann cell columns in humans. Neuropathol Appl Neurobiol. 1993;19(6):500-506.
Gabreëls-Festen AAWM, Bolhuis PA, Hoogendijk JE, Valentijn LJ, Eshuis EJHM, Gabreëls FJM. Charcot-Marie-tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Acta Neuropathol. 1995;90(6):645-649.
Fledrich R, Abdelaal T, Rasch L, et al. Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nature. IDAA Commun. 2018;9(1):3025.
Klein D, Groh J, Wettmarshausen J, Martini R. Nonuniform molecular features of myelinating Schwann cells in models for CMT1: distinct disease patterns are associated with NCAM and c-Jun upregulation. Glia. 2014;62(5):736-750.
Chung KW, Kim SM, Sunwoo IN, et al. A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-tooth disease. J Hum Genet. 2008;53(4):360-364.
Shahrizaila N, Noto Y, Simon NG, et al. Quantitative muscle ultrasound as a biomarker in Charcot-Marie-tooth neuropathy. Clin Neurophysiol. 2017;128(1):227-232.
Wang H, Davison M, Wang K, et al. Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A. Ann Clin Transl Neurol. 2020;7(1):69-82.
Spaulding EL, Hines TJ, Bais P, et al. The integrated stress response contributes to tRNA synthetase-associated peripheral neuropathy. Science. 2021;373(6559):1156-1161.
Niezgoda A, Michalak S, Losy J, Kalinowska-Łyszczarz A, Kozubski W. sNCAM as a specific marker of peripheral demyelination. Immunol Lett. 2017;185:93-97.